Evaluation of Safety, Tolerability, and Pharmacokinetics of HJB647 in Healthy Subjects and Subjects with Elevated Blood Pressure in Heart Failure

The primary objective of this clinical study is to evaluate the **safety**, **tolerability**, and **pharmacokinetics** of HJB647 in both healthy participants and those with elevated blood pressure. This investigation is crucial for understanding the potential therapeutic application of HJB647, particularly in the context of **heart failure (HF)**, a condition characterized by the heart's inability to pump blood effectively, leading to significant morbidity and mortality. The study is designed as a first-in-human, randomized, participant and investigator-blinded, placebo-controlled trial, which includes both single and multiple ascending dose assessments. Additionally, an open-label component will assess drug-drug interactions with a CYP3A inhibitor, providing further insights into the metabolic profile of HJB647.

The clinical trial focuses on individuals diagnosed with **heart failure (HF)**. The study population includes both male and female participants, with an age range categorized as adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants involved in the study. Participants were selected without any specific lifestyle considerations such as diet, physical activity, or habits being highlighted. The sponsor has not disclosed any key inclusion or exclusion criteria for this trial.

The clinical trial is designed as a **randomized**, participant and investigator **blinded**, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of HJB647. The trial will include both single and multiple ascending dose phases and will involve healthy participants as well as otherwise healthy participants with elevated blood pressure. Additionally, there is an open-label component to assess drug-drug interactions with a **CYP3A inhibitor**. The study is focused on participants with **heart failure** and is classified as a Phase 1 trial.

The trial is expected to commence recruitment on November 13, 2023, and is projected to conclude by September 30, 2025. Participants will be involved in the study for a duration that aligns with the trial's timeline, subject to their continued eligibility and adherence to the study protocol. The trial will include a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will undergo baseline assessments before randomization.

Subsequent visits will be scheduled to monitor safety, tolerability, and pharmacokinetic parameters at specified intervals. These follow-up visits are critical for collecting data on the investigational product's effects and any adverse events. The end-of-study visit will mark the completion of the participant's involvement, during which final assessments will be conducted to ensure participant safety and gather concluding data.

Participants may be withdrawn from the study prematurely if they experience significant adverse events, fail to comply with the study protocol, or if the investigator deems it necessary for their safety. The trial's design and procedures are structured to ensure rigorous data collection while prioritizing participant safety throughout the study duration.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the provided data, further details about the **experimental medication** and any **non-experimental treatments** used in the study cannot be elaborated upon. The trial documentation should be consulted for comprehensive information regarding the treatments involved in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, focusing on initial safety and efficacy assessments. The estimated recruitment start date is November 13, 2023, with an anticipated end date of September 30, 2025. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve the collection of preliminary data on the drug's effects, which may include **biomarker** levels or other relevant clinical measures. The trial will likely employ validated scales and laboratory tests to gather data at predetermined intervals throughout the study period. The analysis of these parameters will be conducted to determine the initial efficacy profile of the investigational product. The trial's design and methodology will adhere to regulatory standards to ensure the reliability and validity of the efficacy assessments.